Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw as Chief Medical Officer

Toronto, Ontario --News Direct-- Helix BioPharma Corp.

October 3, 2022 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX:HBP) (OTC:HBPCF) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce the appointment of Dr. Frank Gary Renshaw, as the Chief Medical Officer.

Dr. Renshaw has been with Helix since December 2019 as a consultant and member of the Scientific and Strategic Advisory Board. He brings more than 20 years’ experience as a drug developer within the health care industry and has previously provided leadership with his medical and/or scientific expertise, from pre-clinical laboratory and animal tumor model development, to presiding over six successful new drug applications, eight approvals at the EMA, including two biological applications, and more than two dozen successful FIH IND’s and EMA new drug submissions.

Recently, he has provided further expertise as the Chief Medical Officer, and lead Oncology consultant for several Bio-Pharmaceutical global entities, as well as the Global lead on many radiotherapies, Chemotherapy, Devices, and Immuno-Oncology clinical programs.

“Dr. Renshaw will bring to Helix BioPharma his several decades of development experience in oncology-hematology, Molecular/Immuno-Oncology drug research. We look forward to his leadership in helping shape the future of our work at Helix.”, said Artur Gabor, Helix’s Chief Executive Officer.

Dr. Renshaw stated, "L-DOS47 has the potential to enhance the efficacy of chemo- and IO-therapies for treatment of various tumors by modulating the tumor microenvironment. *With promising data already generated from preclinical experiments and previous clinical trials, I am excited to lead the next phase of clinical development to bring this improved therapy for cancer patients at the earliest.”

Frank Gary Renshaw Bio

Dr. Frank Gary Renshaw is an Oncologist-Hematologist having completed his training at the medical school at University of Medicine and Dentistry of New Jersey at the Cardeza Foundation and Temple University Skin and Cancer Hospital and was a resident within the Oncology immunology research group at the Cancer Institute of NJ. Subsequent to this, he trained during his Oncology fellowship with the Cancer Immuno-Biological therapy group at MD Anderson Cancer Center and completed a molecular Biology fellowship at the NIH Naval Medical center where he worked on FIH trials of T-Cell therapy. During his academic career he worked as an Oncology consultant and Primary investigator to the Glaxo Smith Kline, Immunex, Chiron, Bristol Myers Squibb, and Sinclair Swine melanoma research, companies. From his academic rolls, Dr. Renshaw was then recruited to chair the US Gastrointestinal Oncology group at Eli Lilly company, leading several early development programs as well as the later stages of drug clinical/research development of Gemcitabine, and including pharmacogenetic/dynamics work for the eventual multiple approvals Pemetrexed for NSCLC and Mesothelioma.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer, based on the proprietary technology platform DOS47. Helix is listed on the TSX under the symbol “HBP.”

For more information, please contact:

Helix BioPharma Corp.

Suite 2704, 401 Bay Street Toronto, Ontario, M5H 2Y4

Tel: 905-841-2300

Namrata Malhotra, Corporate Secretary

namrata@grovecorp.ca

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to DOS47, and statements regarding expected improvements to the Company’s independence, diversification and corporate governance and the Company’s expectations regarding strengthening its future growth capabilities. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward- looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management’s current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release.

The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation; the risk that the Company’s assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company’s research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company’s anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company’s annual management’s discussion and analysis for the year ended July 31, 2021 under the heading “Risks and Uncertainties” and Helix’s Annual Information Form, in particular under the headings “Forward-looking Statements” and “Risk Factors”, and other reports filed under the Company’s profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

View source version on newsdirect.com: https://newsdirect.com/news/helix-biopharma-corp-appoints-dr-frank-gary-renshaw-as-chief-medical-officer-420939737